MD Biosciences Expands Its US Preclinical Contract Research Laboratory to Provide Additional Capacity for New Areas of Research

Share Article

Expansion provides increased capacity, ability to add new models as well as continue the development of new methods and biomarkers that bring clinical insight to the nonclinical drug development phase.

MD Biosciences, a preclinical, non-clinical contract research group (CRO)
Our global laboratories in the US, UK and Israel are positioned to be able to serve each market and research niche efficiently with strong scientific insight.

MD Biosciences, a global preclinical contract research organization (CRO), announces the expansion of its preclinical contract research laboratory in St Paul, MN. The expansion of the laboratory provides additional capacity to increase the in vivo research models of its inflammations division. Additionally, adding capabilities in the areas of metabolic and cancer research are underway with metabolic studies already being offered. As part of this expansion, MD Biosciences is also hiring experienced scientists in these areas to join our St Paul research team. The lab operates under a full IACUC committee and is currently in process of applying for AAALAC acreditation, which the aim is to achieve by the end of 2013.

As biopharma companies are dealing with reduced R&D budgets and pressures to replace revenue from patent expirations, bringing a clinical mindset to non-clinical study design assists in translating preclinical data human disease. MD Biosciences is continually developing new methods that help address the gap between non-clinical data and clinical outcomes. Often times existing preclinical disease models are all that is available but don’t necessarily reflect what is seen in the clinic – additional capacity enables MD Biosciences to continue its R&D program in search of new and more relevant preclinical models and biomarkers.

MD Biosciences currently offers a wide selection of in vivo models within inflammation/autoimmune, CNS, pain, wound healing and cardiovascular fields of research. Its focus is on the cross-talk between the immune and nervous systems and the areas of overlap as well as contributions of one to the other in disease pathways. This deep understanding in the cross-talk and a strict focus on sponsors objectives enables MD Biosciences to contribute to the overall study design.

"The expansion of the preclinical contract research lab in the US assists us in serving both North American and International clients. Our global laboratories in the US, UK and Israel are positioned to be able to serve each market and research niche efficiently with strong scientific insight. Our approach to deeply understand each sponsors objectives allows us to contribute and invest scientifically in their program," says CEO Eddie Moradian.

More extensive information on the models offered can be found on MD Biosciences website.

About MD Biosciences
MD Biosciences is a global preclinical contract research organization (CRO) specializing in the areas of inflammation/autoimmune, CNS and cardiovascular. Our focus is not only on the science but also on the understanding of our clients’ objectives. Research facilities are located in the US, UK and Israel – all strategically located within strong scientific and collaborative networks. The flexible, responsive and collaborative approach combined with a strong scientific understanding of systems cross-talk offers a unique partnership to the biopharma and medical device community.

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Follow us on
Visit website